Jefferies Believes Vertex Pharmaceuticals (NASDAQ: VRTX) Won’t Stop Here

By Ryan Adsit

In a report released today, Biren Amin from Jefferies reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX), with a price target of $126. The company’s shares opened today at $122.66, close to its 52-week high of $130.69.

According to TipRanks.com, Amin is a 4-star analyst with an average return of 3.9% and a 48.4% success rate. Amin covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Stemline Therapeutics Inc, and Lion Biotechnologies Inc.

Currently, the analyst consensus on Vertex Pharmaceuticals is Moderate Buy and the average price target is $127.80, representing a 4.2% upside.

In a report issued on June 1, Oppenheimer also upgraded the stock to Buy with a $150 price target.

Vertex Pharmaceuticals’ market cap is currently $31.34B and has a P/E ratio of 179.87. The company has a book value ratio of 20.8918.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.